Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION phase 2 single-arm study of tepotinib in advanced non-small cell lung cancer with MET exon 14 skipping or MET amplification
MOH_2019-06-19_007213Phase 2Active, not recruiting
- Sponsor
- Merck KGaA
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Feb 2019; status: active, not recruiting.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-06-19_007213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-19_007213.